Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Gastro-enteropancreatic neuroendocrine tumor × zimberelimab × 90 days × Clear all

Sponsor

Conditions

Stomach Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Uterine Cervical Neoplasms 3 Carcinoma, Renal Cell 3 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Pancreatic Neoplasms 2 Neoplasm Metastasis 2 Lung Neoplasms 2 Kidney Neoplasms 2 Adenocarcinoma Of Esophagus 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Urothelial Bladder Carcinoma 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Solid Tumor 1 Ovarian Neoplasms 1 Neoplasms 1 Metastatic Urothelial Cancer 1 Glioblastoma 1 Esophageal Neoplasms 1 Erythrocytosis, Familial, 4 1 Cholangiocarcinoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Neuroendocrine 1 Bile Duct Neoplasms 1 Advanced Solid Tumor 1

Interventions

lutetium Lu 177 dotatate 3 pasireotide 2 Octreotide 2 lanreotide 1 copper dotatate CU-64 1 abemaciclib 1 Sunitinib 1 Receptor-Like Protein Tyrosine Phosphatases, Class 2 1 Lutetium-177 1 Lutetium 1 Everolimus 1 E-7386 1 Cryotherapy 1 Acupuncture Therapy 1 Acupressure 1 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡